Earlier this year, in an unprecedented, fast-tracked review, the FDA approved Keytruda as the first immunotherapy treatment for advanced pancreatic cancer patients whose tumors are mismatch repair deficient. This deficiency alters the ability to repair DNA, which is a factor in cancer development. It is estimated that approximately 1 in 50 advanced pancreatic cancer patients have tumors that are mismatch repair deficient.
The Lustgarten Foundation played a critical role in bringing Keytruda to pancreatic cancer patients by funding this innovative research, encouraging patients to get their tumors tested, and covering the cost of the test. Congratulations to our Distinguished Scholar Dr. Bert Vogelstein and his team at the Johns Hopkins Kimmel Cancer Center for this great honor and tremendous accomplishment.
Watch our video to learn more.